Briefing: Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle

Pfizer has developed a new vaccine targeting Lyme disease, which impacts nearly half a million Americans annually.

While the vaccine has shown some efficacy in trials, it did not meet a significant statistical hurdle necessary for broader approval.

This outcome may influence future vaccine development strategies and public health responses to Lyme disease.